Key Takeaways
Sanofi SA (EURONEXT: SAN) received a positive recommendation from a key European Medicines Agency panel for its multiple sclerosis drug tolebrutinib, setting up a potential approval for the first oral BTK inhibitor for non-relapsing secondary progressive MS (SPMS).
The Committee for Medicinal Products for Human Use (CHMP) based its positive opinion on data from the HERCULES phase 3 study, which demonstrated that the brain-penetrant drug significantly delayed the onset of disability progression in patients. "Cenrifki represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological diseases," the company said in a statement.
A final decision on the marketing authorization from the European Commission is expected in the coming months. The positive opinion was supported by data from the GEMINI 1 and GEMINI 2 phase 3 studies in relapsing multiple sclerosis.
Approval would give Sanofi a key entry into the competitive market for Bruton’s tyrosine kinase (BTK) inhibitors for MS, where it will likely compete with Genentech’s fenebrutinib, which recently showed over a 50% relapse reduction versus Sanofi's own Aubagio in separate trials.
The positive opinion for tolebrutinib, to be marketed as Cenrifki, follows recent late-breaking data from rival Genentech, a Roche subsidiary, on its own BTK inhibitor, fenebrutinib. In two large Phase 3 trials, fenebrutinib demonstrated a greater than 50% reduction in relapse rates compared to Aubagio (teriflunomide) in patients with relapsing forms of MS. This highlights a new front in the MS treatment landscape, with multiple companies vying for dominance in the novel BTK inhibitor class.
While the efficacy data for the new class of BTK inhibitors is promising, safety remains a key focus for regulators. Sanofi noted that drug-induced liver injury (DILI) is an identified risk for tolebrutinib, requiring strict adherence to liver monitoring requirements. Genentech's fenebrutinib trials also saw seven deaths in the treatment arm versus one in the comparator group, though researchers noted a lack of clustering that would point to a mechanism-specific cause.
The CHMP backing significantly de-risks the European approval pathway for Cenrifki and provides a much-needed boost to Sanofi's neurology pipeline. For patients with non-relapsing SPMS, a condition with few treatment options, the potential approval of a new oral therapy targeting disability progression marks a significant development. Investors will now await the final European Commission decision and further regulatory filings worldwide.
This article is for informational purposes only and does not constitute investment advice.
